Axi-cel and tisa-cel are prescribed to distinct patient populations, possibly due to differing CAR-T manufacturing times, and differences in resource utilization.
Results of a prospective phase 3 study demonstrated noninferiority of R-THP-COP for diffuse large B cell lymphoma to the standard of care, suggesting the regimen may be an alternative option for these patients.
Patients with diffuse large B-cell lymphoma, which often relapses and kills within 2 years, experienced a remission of their cancer and stayed disease-free as long as 28 months after taking a commercially available drug that made chemotherapy more effective.
Management and prognosis for patients with NHL depend on identifying the disease type. This review discusses the diagnoses and optimal treatments.
Smoking appears to increase the risk of Hodgkin’s lymphoma, a prospective study has shown.
